Patients on liraglutide (Saxenda) had sustained weight loss over three years with diet and exercise, researchers reported. Mean weight loss was 6.1% of body weight with the drug versus 1.9% with placebo for the more than 2,000 patients in an extension of a phase III trial who had either prediabetes and obesity, or were overweight with comorbidities (an estimated treatment difference of 4.3%, 95% CI -4.9 to -3.7; P<0.0001). Half of the patients on liraglutide achieved ≥5% weight loss as opposed to 24% of those on placebo (odds ratio 3.2, 95% CI 2.6-3.9; P<0.0001). A quarter of patients on the drug, versus 9.9% in the placebo group, achieved >10% weight loss (OR 3.1, 95% CI 2.3-4.1; P<0.0001).  Of 2,254 patients, 1,128 completed 160 weeks of the trial (52.6% of those on liraglutide and 45.0% of those on placebo). And the time to onset of type 2 diabetes was 2.7 times longer with liraglutide than with placebo (95% CI 1.9-3.9), while the risk of developing diabetes was lower with liraglutide (1.8% versus 6.2%; P<0.0001). The authors concluded that the drug was “generally well tolerated.” Patients were randomized 2:1 to once daily liraglutide 3.0 mg or to placebo, and all were advised to consume a 500kcal/day deficit diet (i.e., eat 500 kcal less than their estimated daily energy expenditure) and 150 minutes per week of exercise. Le Roux C, et al “Reduction in the risk of developing type 2 diabetes (T2D) with liraglutide 3.0 mg in people with pre-diabetes from the SCALE obesity and pre-diabetes randomized, double-blind, placebo-controlled trial” Obesity Week 2015; T-P-LB-3843.